Simona Grozinsky-Glasberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Simona Grozinsky-Glasberg has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Ilan Shimon
Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
7 shared publicationsDganit Barak
Hebrew University of Jerusalem
3 shared publications- Gregory Kaltsas
1st Propaedeutic Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
3 shared publications Alexander Gorshtein
Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
2 shared publicationsAshley Grossman
2 shared publicationsDavid J. Gross
Endocrinology and Metabolism Service, Department of Medicine, Hadassah‐Hebrew University Medical Center, Jerusalem, Israel
2 shared publications
Latest Publications
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Patients with metastatic bone disease and neuroendocrine neoplasms: the experience of a multi-center study
Introduction: Neuroendocrine neoplasms (NENs) have variable biological behavior but the majority exhibits a slow progression. Metastatic bone disease (mBD) in NENs is relatively uncommon and not well described albeit associated with an increased mortality. Methods: Seventy-four [37 males (50%), aged(±S.D.) 60.2±19.3] patients with NENs and bone metastases were recruited from 4 centers. Results: Seventy-three (98.6%) patients had sporadic disease while 1(1.4%) had MEN-1. The primary disease sites were: pancreas: 22(29.2%); small bowel: 18(24.3%); unknown origin: 12(16.2%); lung: 11(14.9%); sigmoid: 4(9.5%), thymus: 2(2.7%), breast: 1(1.4%) and caecum 1(1.4%). Four (5.4%) had functional syndrome, 2 ACTH-ectopic syndrome and 2 carcinoid syndrome. Thirty-four (46%) patients had synchronous diagnosis of NEN and mBD, while in the remaining the time to mBD since first diagnosis was 27.9±56.7(0-383) months. Metastatic deposits were found as following: liver 48(64.9%), lymph nodes 24(32.4%), adrenal gland 4(5.4%), lymph nodes 11(14.9%), retroperitoneal and pelvic implantation 2(2.7%), mediastinum 2(2.7%), orbital brain 2(2.7%), brain 1(1.4%), parotid gland 1(1.4%), ovaries and uterus 1(1.4%), pancreas 1(1.4%). Sixteen (28.1%) patients had Ki-67≤2% (grade 1), 27(47.4%) 3-20% (grade 2), 25(15.8%) >20% (grade 3) for gastro-intestinal NENs and for lung and thymus all 9(15.8%) had atypical NENs. The treatment for mBD included bisphosphonates in 40 (74%), peptide receptor radionuclide therapy (PRRT) 29(39.2%), denosumab 13(17.6%), and RT 13(17.6%). The imaging studies dentified mBD as following: 45/54(83.3%) bone scan, 21/35(60%) MRI, 36/67(53.7%) CT, 35/54(64.8%) octreoscan, 11/21(52.4%) PET-FDG and 28/30(93.3%) gallium-68 positron emission tomography (Ga-PET). The mBD therapy resulted in improvement in 6.3%, stable disease in 45.3%, and deterioration in 37.5% while 10.9% of patients passed away before the evaluation of treatment response. No difference was seen after treatment with an intensified bishphosphonate scheme (4 mg of zoledronic acid monthly for 2 consecutive years) versus a conventional scheme. Overall, 30(40.5%) patients succumbed because of their disease with an overall survival 67.1±76(1-447) months since the NEN diagnosis. Conclusion: The present multicentre registry of patients with NENs and mBD highlights the validity of Ga-PET for mBD identification and implies that there is no need of an intensified treatment at least for bisphosphonates despite the higher mortality rate of this subgroup of patients with NENs.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Patients with metastatic bone disease and neuroendocrine neoplasms: the experience of a multi-center study
Introduction: Neuroendocrine neoplasms (NENs) have variable biological behavior but the majority exhibits a slow progression. Metastatic bone disease (mBD) in NENs is relatively uncommon and not well described albeit associated with an increased mortality. Methods: Seventy-four [37 males (50%), aged(±S.D.) 60.2±19.3] patients with NENs and bone metastases were recruited from 4 centers. Results: Seventy-three (98.6%) patients had sporadic disease while 1(1.4%) had MEN-1. The primary disease sites were: pancreas: 22(29.2%); small bowel: 18(24.3%); unknown origin: 12(16.2%); lung: 11(14.9%); sigmoid: 4(9.5%), thymus: 2(2.7%), breast: 1(1.4%) and caecum 1(1.4%). Four (5.4%) had functional syndrome, 2 ACTH-ectopic syndrome and 2 carcinoid syndrome. Thirty-four (46%) patients had synchronous diagnosis of NEN and mBD, while in the remaining the time to mBD since first diagnosis was 27.9±56.7(0-383) months. Metastatic deposits were found as following: liver 48(64.9%), lymph nodes 24(32.4%), adrenal gland 4(5.4%), lymph nodes 11(14.9%), retroperitoneal and pelvic implantation 2(2.7%), mediastinum 2(2.7%), orbital brain 2(2.7%), brain 1(1.4%), parotid gland 1(1.4%), ovaries and uterus 1(1.4%), pancreas 1(1.4%). Sixteen (28.1%) patients had Ki-67≤2% (grade 1), 27(47.4%) 3-20% (grade 2), 25(15.8%) >20% (grade 3) for gastro-intestinal NENs and for lung and thymus all 9(15.8%) had atypical NENs. The treatment for mBD included bisphosphonates in 40 (74%), peptide receptor radionuclide therapy (PRRT) 29(39.2%), denosumab 13(17.6%), and RT 13(17.6%). The imaging studies dentified mBD as following: 45/54(83.3%) bone scan, 21/35(60%) MRI, 36/67(53.7%) CT, 35/54(64.8%) octreoscan, 11/21(52.4%) PET-FDG and 28/30(93.3%) gallium-68 positron emission tomography (Ga-PET). The mBD therapy resulted in improvement in 6.3%, stable disease in 45.3%, and deterioration in 37.5% while 10.9% of patients passed away before the evaluation of treatment response. No difference was seen after treatment with an intensified bishphosphonate scheme (4 mg of zoledronic acid monthly for 2 consecutive years) versus a conventional scheme. Overall, 30(40.5%) patients succumbed because of their disease with an overall survival 67.1±76(1-447) months since the NEN diagnosis. Conclusion: The present multicentre registry of patients with NENs and mBD highlights the validity of Ga-PET for mBD identification and implies that there is no need of an intensified treatment at least for bisphosphonates despite the higher mortality rate of this subgroup of patients with NENs.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Clinical features of 'dedifferentiation' in advanced pancreatic neuroendocrine neoplasms: the experience of two centers of excellence
Introduction: Neuroendocrine neoplasms (NENs) exhibit significant heterogeneity in growth rates. Clinical and histopathological dedifferentiation has been documented but their clinical characteristics have not been described. Aim of the study: The identification of clinical features of a series of pancreatic NENs (pNENs) that developed dedifferentiation during their course. Methods: Fourteen patients (eight males) with mean age(±S.D.): 54.8±12.4 years were recruited from two centers. Patients with documented disease progression were submitted to a new biopsy. Dedifferentiation was defined as histologically proven higher Ki-67 (%) able to increase the grade of neoplasm. Immunohistochemical analysis (IHC) for p53, β-catenin and E-cadherin were studied as markers of aggressive behavior. Results: Twelve (85.7%) patients with a >10% change in Ki-67 had sporadic pNENs and 2 with β-catenin and E-cadherin had unaltered pattern of expression. Conclusions: Dedifferentiation of NENs is associated with a more aggressive behavior and worse overall survival. More studies are needed to clarify if p53 may be used as immunohistochemical marker of dedifferentiation.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Clinical features of 'dedifferentiation' in advanced pancreatic neuroendocrine neoplasms: the experience of two centers of excellence
Introduction: Neuroendocrine neoplasms (NENs) exhibit significant heterogeneity in growth rates. Clinical and histopathological dedifferentiation has been documented but their clinical characteristics have not been described. Aim of the study: The identification of clinical features of a series of pancreatic NENs (pNENs) that developed dedifferentiation during their course. Methods: Fourteen patients (eight males) with mean age(±S.D.): 54.8±12.4 years were recruited from two centers. Patients with documented disease progression were submitted to a new biopsy. Dedifferentiation was defined as histologically proven higher Ki-67 (%) able to increase the grade of neoplasm. Immunohistochemical analysis (IHC) for p53, β-catenin and E-cadherin were studied as markers of aggressive behavior. Results: Twelve (85.7%) patients with a >10% change in Ki-67 had sporadic pNENs and 2 with β-catenin and E-cadherin had unaltered pattern of expression. Conclusions: Dedifferentiation of NENs is associated with a more aggressive behavior and worse overall survival. More studies are needed to clarify if p53 may be used as immunohistochemical marker of dedifferentiation.
- 1 March 2014
- Published by Bioscientifica in Endocrine Abstracts
Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells
Pancreatic neuroendocrine tumours (NETs) are reported to show frequent mutations in chromatin remodelling genes, while pituitary NETS have alterations in histone modification. Histone modifications, and specifically acetylated residues on histone tails are recognised by members of the bromo and extra terminal (BET) protein family, via their bromodomains, causing alterations in the transcription of growth stimulating genes. BET bromodomain inhibitors have been demonstrated to successfully reduce tumour growth in mouse models, including those for nuclear protein in testis (NUT)-midline carcinoma, non-small cell lung cancer, leukaemia and glioblastoma. We therefore assessed the efficacy of two pan-BET inhibitors, JQ1 and PFI-1, on proliferation, apoptosis and senescence of three human NET cell lines (BON-1 cells derived from a pancreatic NET, and H727 and H720 cells derived from lung NETs) and one mouse cell line (AtT20 cells derived from the pituitary). Proliferation was assessed by the Cell Titre Blue fluorescent assay, apoptosis by caspase 3/7 cleavage, and cellular senescence by β-galactosidase (X-gal) staining. Our results show that JQ1 and PFI-1 had significant effects on proliferation, apoptosis and senescence. Thus, in all four cell lines JQ1 reduced proliferation by up to 95% (P60 of 36 nM, while PFI-1 reduced proliferation by up to 40% (P≤0.0002), with an average IC60 of 800 nM. JQ1 also significantly increased apoptosis by up to 3.5-fold (PPP0.0005). Thus, our data demonstrate that BET protein inhibitors may represent potential compounds for the treatment of neuroendocrine tumours.
- 1 March 2014
- Published by Bioscientifica in Endocrine Abstracts
Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells
Pancreatic neuroendocrine tumours (NETs) are reported to show frequent mutations in chromatin remodelling genes, while pituitary NETS have alterations in histone modification. Histone modifications, and specifically acetylated residues on histone tails are recognised by members of the bromo and extra terminal (BET) protein family, via their bromodomains, causing alterations in the transcription of growth stimulating genes. BET bromodomain inhibitors have been demonstrated to successfully reduce tumour growth in mouse models, including those for nuclear protein in testis (NUT)-midline carcinoma, non-small cell lung cancer, leukaemia and glioblastoma. We therefore assessed the efficacy of two pan-BET inhibitors, JQ1 and PFI-1, on proliferation, apoptosis and senescence of three human NET cell lines (BON-1 cells derived from a pancreatic NET, and H727 and H720 cells derived from lung NETs) and one mouse cell line (AtT20 cells derived from the pituitary). Proliferation was assessed by the Cell Titre Blue fluorescent assay, apoptosis by caspase 3/7 cleavage, and cellular senescence by β-galactosidase (X-gal) staining. Our results show that JQ1 and PFI-1 had significant effects on proliferation, apoptosis and senescence. Thus, in all four cell lines JQ1 reduced proliferation by up to 95% (P60 of 36 nM, while PFI-1 reduced proliferation by up to 40% (P≤0.0002), with an average IC60 of 800 nM. JQ1 also significantly increased apoptosis by up to 3.5-fold (PPP0.0005). Thus, our data demonstrate that BET protein inhibitors may represent potential compounds for the treatment of neuroendocrine tumours.
- 1 March 2014
- Published by Bioscientifica in Endocrine Abstracts
Inhibition of human NET cell proliferation by a peptide identified through phage display screening
Neuroendocrine tumours (NETs) occur in multiple sites including, the pancreas, gastrointestinal tract, lung, thymus, parathyroid, adrenals and pituitary. Current treatments for advanced NETs such as surgery, chemotherapy or radiotherapy, rarely achieve a cure due to metastases at presentation therefore additional therapeutic treatments are required. Identification of cell surface receptors or binding sites that are unique or up-regulated on tumour or neuroendocrine tissue could lead to novel targeted drugs, radio-isotope or gene therapy treatments. To identify ligands to such receptors we used a phage display selection technique in which a library of peptides is expressed on the outside of phage virions, with each virion displaying a unique peptide encoded by the genetic material inside. Three rounds of phage display screening using a 12-mer library (New England BioLabs) to three human neuroendocrine (carcinoid) cell lines, BON-1, H727 and H720, which were shown to express chromogranin A, neuron specific enolase and menin, was performed and binding phage identified. A lead candidate peptide ALWPPNLHAWVP emerged since it was recovered in 81% of BON-1 cell binding clones and 73% of H727 cell binding clones, with the frequency of ALWPPNLHAWVP-bearing phage increasing from the second to the third round, confirming that this peptide was enriched during screening. Incubation of BON-1 cells with biotinylated ALWPPNLHAWVP peptide or a scrambled peptide control followed by FITC–avidin and confocal microscopic analysis confirmed the ability of the peptide to bind to these cells. Application of 10 μM ALWPPNLHAWVP mediated a 70% decrease (PPP<0.02) increase in apoptosis, without an increase in cell senescence. Thus, our studies have identified a peptide that may play a role in targeting NET cells and in reducing NET tumour growth.
- 1 March 2014
- Published by Bioscientifica in Endocrine Abstracts
Inhibition of human NET cell proliferation by a peptide identified through phage display screening
Neuroendocrine tumours (NETs) occur in multiple sites including, the pancreas, gastrointestinal tract, lung, thymus, parathyroid, adrenals and pituitary. Current treatments for advanced NETs such as surgery, chemotherapy or radiotherapy, rarely achieve a cure due to metastases at presentation therefore additional therapeutic treatments are required. Identification of cell surface receptors or binding sites that are unique or up-regulated on tumour or neuroendocrine tissue could lead to novel targeted drugs, radio-isotope or gene therapy treatments. To identify ligands to such receptors we used a phage display selection technique in which a library of peptides is expressed on the outside of phage virions, with each virion displaying a unique peptide encoded by the genetic material inside. Three rounds of phage display screening using a 12-mer library (New England BioLabs) to three human neuroendocrine (carcinoid) cell lines, BON-1, H727 and H720, which were shown to express chromogranin A, neuron specific enolase and menin, was performed and binding phage identified. A lead candidate peptide ALWPPNLHAWVP emerged since it was recovered in 81% of BON-1 cell binding clones and 73% of H727 cell binding clones, with the frequency of ALWPPNLHAWVP-bearing phage increasing from the second to the third round, confirming that this peptide was enriched during screening. Incubation of BON-1 cells with biotinylated ALWPPNLHAWVP peptide or a scrambled peptide control followed by FITC–avidin and confocal microscopic analysis confirmed the ability of the peptide to bind to these cells. Application of 10 μM ALWPPNLHAWVP mediated a 70% decrease (PPP<0.02) increase in apoptosis, without an increase in cell senescence. Thus, our studies have identified a peptide that may play a role in targeting NET cells and in reducing NET tumour growth.
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors
BACKGROUND: Normal adult lungs contain pulmonary neuroendocrine cells (PNECs). PNEC hyperplasia may be either reactive or idiopathic, and the idiopathic type is defined as diffuse idiopathic PNEC hyperplasia (DIPNECH). It is believed that DIPNECH is a neuroendocrine proliferative process associated with carcinoid tumors. The available data regarding this rare condition are very limited. The objective of the current study was to describe the clinical, radiologic, and pathologic characteristics of patients with DIPNECH and the effect of various therapeutic modalities on patient well being.METHODS: The authors retrospectively studied 11 consecutive patients with DIPNECH who were followed at 2 referral centers in Israel between 2000 and 2010.RESULTS: All patients were women, and their median age was 62.8 years. Six patients presented with respiratory symptoms, such as prolonged dyspnea, wheezing, and cough. All patients had carcinoid tumor together with multiple, small pulmonary nodules observed on thoracic high‐resolution computerized tomography images. The mean size of the dominant lesion was 19.4 ± 9.6 mm. Nine patients underwent thoracotomy and resection of the dominant lesion. The disease was stable in 5 of 11 patients; in 6 of 10 patients, it progressed, and the patients received treatment with somatostatin analogs, which induced disease stabilization in all patients. Metastatic disease was diagnosed in 3 of 11 patients (36%). All patients were alive at the end of follow‐up (mean, 4.63 ± 2.04 years; ongoing).CONCLUSIONS: The association of lung neuroendocrine tumor with multiple nodules in women, together with complains of chronic cough and wheezing, should raise suspicion of DIPNECH. Whenever possible, these patients should undergo surgical excision of the dominant lesion, and somatostatin analogs may be considered for symptomatic or tumor control in patients with progressive disease. Cancer 2012;. © 2011 American Cancer Society.
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors
BACKGROUND: Normal adult lungs contain pulmonary neuroendocrine cells (PNECs). PNEC hyperplasia may be either reactive or idiopathic, and the idiopathic type is defined as diffuse idiopathic PNEC hyperplasia (DIPNECH). It is believed that DIPNECH is a neuroendocrine proliferative process associated with carcinoid tumors. The available data regarding this rare condition are very limited. The objective of the current study was to describe the clinical, radiologic, and pathologic characteristics of patients with DIPNECH and the effect of various therapeutic modalities on patient well being.METHODS: The authors retrospectively studied 11 consecutive patients with DIPNECH who were followed at 2 referral centers in Israel between 2000 and 2010.RESULTS: All patients were women, and their median age was 62.8 years. Six patients presented with respiratory symptoms, such as prolonged dyspnea, wheezing, and cough. All patients had carcinoid tumor together with multiple, small pulmonary nodules observed on thoracic high‐resolution computerized tomography images. The mean size of the dominant lesion was 19.4 ± 9.6 mm. Nine patients underwent thoracotomy and resection of the dominant lesion. The disease was stable in 5 of 11 patients; in 6 of 10 patients, it progressed, and the patients received treatment with somatostatin analogs, which induced disease stabilization in all patients. Metastatic disease was diagnosed in 3 of 11 patients (36%). All patients were alive at the end of follow‐up (mean, 4.63 ± 2.04 years; ongoing).CONCLUSIONS: The association of lung neuroendocrine tumor with multiple nodules in women, together with complains of chronic cough and wheezing, should raise suspicion of DIPNECH. Whenever possible, these patients should undergo surgical excision of the dominant lesion, and somatostatin analogs may be considered for symptomatic or tumor control in patients with progressive disease. Cancer 2012;. © 2011 American Cancer Society.
- 1 January 2011
- Vol. 32 (6) , 735-40
Fulminant ectopic Cushing syndrome in a patient with metastatic neuroendocrine carcinoma and Crohn's disease.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been rarely reported in patients with Crohn's disease, being usually small and incidentally detected in areas uninvolved by the inflammatory process. We describe the case of a young female patient with Crohn's disease and a fulminant Cushing's syndrome induced by the ectopic secretion of adrenocorticotropic hormone (ACTH) by an aggressive gastrointestinal neuroendocrine carcinoma (NEC). Despite a multi-therapeutic approach, including the administration of multiple courses of chemotherapy, hypo-cortisolemic agents, somatostatin analogues, as well as the performance of bilateral adrenal vein embolization followed by bilateral adrenalectomy, patient's condition progressively deteriorated and she died nine months after the diagnosis of NEC due to liver failure. The available literature addressing the possible connection between Crohn's disease and NEC is discussed in detail.
- 1 January 2011
- Vol. 32 (6) , 735-40
Fulminant ectopic Cushing syndrome in a patient with metastatic neuroendocrine carcinoma and Crohn's disease.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been rarely reported in patients with Crohn's disease, being usually small and incidentally detected in areas uninvolved by the inflammatory process. We describe the case of a young female patient with Crohn's disease and a fulminant Cushing's syndrome induced by the ectopic secretion of adrenocorticotropic hormone (ACTH) by an aggressive gastrointestinal neuroendocrine carcinoma (NEC). Despite a multi-therapeutic approach, including the administration of multiple courses of chemotherapy, hypo-cortisolemic agents, somatostatin analogues, as well as the performance of bilateral adrenal vein embolization followed by bilateral adrenalectomy, patient's condition progressively deteriorated and she died nine months after the diagnosis of NEC due to liver failure. The available literature addressing the possible connection between Crohn's disease and NEC is discussed in detail.
- Open Access
Peptide receptor radioligand therapy is an effective treatment for the long‐term stabilization of malignant gastrinomas
BACKGROUND: Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton‐pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.METHODS: We retrospectively studied 11 patients with metastatic gastrinomas followed for a mean period of 6 years. All patients were symptomatically treated with PPIs, and 9 of 11 patients received monthly injections of SSAs; all patients had an Eastern Cooperative Oncology Group score of 0‐1, and received PRRT (90Yttrium‐ or 177Lutetium‐DOTATOC) for progressive disease. Serum gastrin measurements and radiological assessment (using the Response Evaluation Criteria in Solid Tumors criteria) were performed before and every 3‐6 months following PRRT.RESULTS: PRRT induced symptomatic improvement in all patients. The mean serum gastrin decreased significantly from 4831 mI/L to 932.6 mI/L (normal, 40‐108 mI/L; P < .001). Periodic radiological surveillance showed complete response in 1 (9%) patient, partial tumor response in 5/11 (45%) patients, and tumor stabilization in 5/11 (45%) patients. In 7/11 (64%) patients, the antitumor effect of PRRT persisted after a median period of 14 months. Four of 11 (36%) patients died due to tumor progression (median time to progression, 11 months); in this group, the mean survival time after the last PRRT was 14 ± 6.9 months.CONCLUSIONS: PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas. Cancer 2011. © 2010 American Cancer Society.
Open AccessPeptide receptor radioligand therapy is an effective treatment for the long‐term stabilization of malignant gastrinomas
BACKGROUND: Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton‐pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.METHODS: We retrospectively studied 11 patients with metastatic gastrinomas followed for a mean period of 6 years. All patients were symptomatically treated with PPIs, and 9 of 11 patients received monthly injections of SSAs; all patients had an Eastern Cooperative Oncology Group score of 0‐1, and received PRRT (90Yttrium‐ or 177Lutetium‐DOTATOC) for progressive disease. Serum gastrin measurements and radiological assessment (using the Response Evaluation Criteria in Solid Tumors criteria) were performed before and every 3‐6 months following PRRT.RESULTS: PRRT induced symptomatic improvement in all patients. The mean serum gastrin decreased significantly from 4831 mI/L to 932.6 mI/L (normal, 40‐108 mI/L; P < .001). Periodic radiological surveillance showed complete response in 1 (9%) patient, partial tumor response in 5/11 (45%) patients, and tumor stabilization in 5/11 (45%) patients. In 7/11 (64%) patients, the antitumor effect of PRRT persisted after a median period of 14 months. Four of 11 (36%) patients died due to tumor progression (median time to progression, 11 months); in this group, the mean survival time after the last PRRT was 14 ± 6.9 months.CONCLUSIONS: PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas. Cancer 2011. © 2010 American Cancer Society.
- 17 May 2010
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 33 (10) , 739-744
Clinically silent chromaffin-cell tumors: Tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas
Background: Chromaffin-cell tumors (CCT), a rare group of catecholamine producing endocrine neoplasms, are traditionally suspected and diagnosed in patients presenting with episodic hypertension, together with the classic triad of headache, sweating, and tachycardia. Asymptomatic CCT are increasingly diagnosed, frequently as “incidentalomas”. We have conducted a multicenter retrospective study, to assess the characteristics of a group of patients with clinically silent CCT, compared with a group of patients with typical CCT. Methods: Forty-three consecutive patients with CCT (24 with silent and 19 with typical tumors) have been retrospectively studied for a period of up to 20 yr (between 1989 and 2009); clinical picture, biochemical tests, as well as topographic and functional assessment were analyzed at diagnosis and periodically following treatment. Surgical samples were reviewed for neuroendocrine markers and for signs of invasiveness. Results: Patients with clinically silent CCT were significantly older than the typical ones (56.3±3.4 vs 48.0±4.8 yr; pvs 4.6±1.5 cm, pConclusion: Clinically silent CCT are more prevalent than previously reported. With an adequate pre-surgical diagnosis and patient preparation, the prognosis of silent tumors is usually excellent.
- 17 May 2010
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 33 (10) , 739-744
Clinically silent chromaffin-cell tumors: Tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas
Background: Chromaffin-cell tumors (CCT), a rare group of catecholamine producing endocrine neoplasms, are traditionally suspected and diagnosed in patients presenting with episodic hypertension, together with the classic triad of headache, sweating, and tachycardia. Asymptomatic CCT are increasingly diagnosed, frequently as “incidentalomas”. We have conducted a multicenter retrospective study, to assess the characteristics of a group of patients with clinically silent CCT, compared with a group of patients with typical CCT. Methods: Forty-three consecutive patients with CCT (24 with silent and 19 with typical tumors) have been retrospectively studied for a period of up to 20 yr (between 1989 and 2009); clinical picture, biochemical tests, as well as topographic and functional assessment were analyzed at diagnosis and periodically following treatment. Surgical samples were reviewed for neuroendocrine markers and for signs of invasiveness. Results: Patients with clinically silent CCT were significantly older than the typical ones (56.3±3.4 vs 48.0±4.8 yr; pvs 4.6±1.5 cm, pConclusion: Clinically silent CCT are more prevalent than previously reported. With an adequate pre-surgical diagnosis and patient preparation, the prognosis of silent tumors is usually excellent.
- 1 February 2010
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 315 (1-2) , 87-94
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
- 1 February 2010
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 315 (1-2) , 87-94
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
- 1 January 2010
- Published by Springer Nature in Hormones
- Vol. 9 (1) , 87-91
Metastatic bronchial neuroendocrine tumor to the pineal gland: A unique manifestation of a rare disease
Metastatic Neuroendocrine Tumor (NET) to the pineal gland is a unique manifestation previously unreported in the literature. We describe an unusual case of metastatic bronchial NET to the pineal gland in a 71-year-old male patient. His primary NET had been resected six years previously and there was no indication of the presence of disseminated metastatic disease at that time. Due to increased uptake by the pituitary gland on the post-operative 111Indium-pentetreotide scintigraphy (Octreoscan), an intra-sellar mass was diagnosed and excised using a transsphenoidal approach; histology revealed an unrelated non-functional pituitary macroadenoma. Four years later, a new mass appeared on MRI, involving the pineal gland, and was diagnosed on biopsy as a metastatic lesion from the original bronchial NET. Since this lesion was not accessible to surgery, it was treated successfully with radiosurgery. The case suggests that NETs should be considered in the differential diagnosis of pineal gland metastases and that radiosurgery may be an effective alternative in the treatment of these patients.
- 1 January 2010
- Published by Springer Nature in Hormones
- Vol. 9 (1) , 87-91
Metastatic bronchial neuroendocrine tumor to the pineal gland: A unique manifestation of a rare disease
Metastatic Neuroendocrine Tumor (NET) to the pineal gland is a unique manifestation previously unreported in the literature. We describe an unusual case of metastatic bronchial NET to the pineal gland in a 71-year-old male patient. His primary NET had been resected six years previously and there was no indication of the presence of disseminated metastatic disease at that time. Due to increased uptake by the pituitary gland on the post-operative 111Indium-pentetreotide scintigraphy (Octreoscan), an intra-sellar mass was diagnosed and excised using a transsphenoidal approach; histology revealed an unrelated non-functional pituitary macroadenoma. Four years later, a new mass appeared on MRI, involving the pineal gland, and was diagnosed on biopsy as a metastatic lesion from the original bronchial NET. Since this lesion was not accessible to surgery, it was treated successfully with radiosurgery. The case suggests that NETs should be considered in the differential diagnosis of pineal gland metastases and that radiosurgery may be an effective alternative in the treatment of these patients.